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Amyotrophic lateral sclerosis (ALS) is the most frequent adult-onset motor neuron disease. Approximately 20% cases of familial
ALS show the mutation in the superoxide dismutase-1 (SOD1) gene. We previously demonstrated that homologue to E6AP
carboxyl terminus- (HECT-) type ubiquitin protein E3 ligase (NEDL1) physically bind to mutated SOD1 protein but not wild-
type SOD1 and promote the degradation of mutated SOD1 protein through ubiquitin-mediated proteasome pathway. To further
understand the role of NEDL1 involved in the pathogenesis of familial ALS, we generated transgenic mice with human NEDL1
cDNA. The transgenic mice with human NEDL1 expression showed motor dysfunctions in rotarod, hanging wire, and footprint
pattern examination. Histological studies indicated degeneration of neurons in the lumbar spinal cord and muscle atrophy. The
number ofactivated microglia inthespinalcordoftransgenic mice was signiﬁcantly higher thanthat ofwild-type mice, suggesting
that inﬂammation might be observed in the spinal cord of transgenic mice. In conclusion, these ﬁndings suggest that the human
NEDL1 transgenic mice might develop ALS-like symptoms, showing signs of motor abnormalities, accompanied with signiﬁcant
reduction in muscle strength.
1.Introduction
Amyotrophic lateral sclerosis (ALS) is an adult-onset motor
neuron disease is characterized by selective degeneration of
motor neurons in the brain and spinal cord, resulting in
progressive paralysis of limb, facial, and respiratory muscles
and death within few years [1, 2]. However, the precise
mechanisms underlying the selective loss of motor neurons
remain elusive. The pathological hallmarks of ALS are the
atrophy of dying motor neurons and the accumulation of the
Lewy body-like inclusions [3] and Skein-like inclusions [4]
in the degenerated motor neurons which is surrounded by
reactive astrocytes [5]a n dm i c r o g l i a[ 6].
The exact composition of such inclusions is incompletely
understood, although the protein identiﬁed so far includes
ubiquitin [7], Cu/Zn superoxide dismutase 1 (SOD1) [8],
Dorﬁn (a RING-ﬁnger-type E3 ubiquitin ligase) [9], and
NEDL1 (NEDD4-like ubiquitin protein ligase-1), which has
been identiﬁed as a novel gene expressed signiﬁcantly at
highlevelsinfavorableneuroblastomarelativetounfavorable
ones [10]. NEDL1 encodes HECT-type E3 ubiquitin ligase
and is detected speciﬁcally in human neuronal tissues,
suggesting that NEDL1 might be involved in the regulation
of the spontaneous regression of favorable neuroblastomas
caused by apoptosis and/or neuronal diﬀerentiation [10].
Interestingly, NEDL1 binds to mutant SOD1 and promotes
degradation of mutated SOD1 protein. The property of
NEDL1 protein is also aﬀected by binding with mutated
SOD1 protein [10] .T h eb i o l o g i c a lr o l eo fN E D L 1i n v o l v e d
in the pathogenesis of ALS is incompletely understood.
Therefore, we generated the human NEDL1 transgenic
(hNEDL1-Tg) mice and studied the several behavioral
batteries of test including hanging wire test, rotarod test,
and foot print test. Here, we found that the hNEDL1-Tg
mice exhibited decreased locomotor activity compared with
wild-typemiceanddevelopedALS-likesymptoms,including2 Journal of Biomedicine and Biotechnology
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Figure 1: Characterization of CAG/hNEDL1 transgenic mice. (a) Schematic representation of CAG/hNEDL1 construction, in which CAG
promoter contains the cytomegalovirus enhancer and a chicken β-actin promoter and intron. (b) Semiquantitative RT-PCR analyses of the
RNAsamplesextractedfromliver,skeletalmuscle,kidney,andbrainofbothwild-typeandtransgenicmicewerecarriedoutandGAPDHwas
used as control in this test. (c) Western blotting analyses of human hNEDL1 protein in diﬀerent tissues of both wild-type and hNEDL1-Tg
mice were carried out and β-actin was used as loading control.
motor neuron degeneration, decreased axon, and microglia
activation in the lumbar spinal cord and muscle weakness.
2.MaterialsandMethods
2.1. Generation of hNEDL1-Tg Mice. The plasmid that
contained the human NEDL1 cDNA was generated by PCR,
and the accession number of human NEDL1 nucleotide
sequence is NM 015052 in Genbank/EBI Data Bank [10].
The NEDL1 cDNA with Kozak sequence that was subcloned
into the pCAGGS expression vector [11] contained the
regulatory elements of the CAG promoter and linearized
SalI and BamHI sites (Figure 1(a)). Transgenic mice were
generated by pronuclear injection of the puriﬁed DNA
fragment (3ng/μL) into fertilized eggs obtained from
intercrosses between C57BL/6J (CLEA, JAPAN) [12]. The
injected eggs were transferred to pseudopregnant recipients.
This resulted in 4 transgenic lines identiﬁed by PCR and
each progeny was analyzed for the hNEDL1 expression by
semiquantitative RT-PCR and Western blotting analyses. A
transgenic line which showed the strongest expression level
of hNEDL1 was used in this study. The mice were housed in
at e m p e r a t u r e -( 2 4± 2◦C) and humidity- (40%−60%)
controlled room with a 12:12hr light-dark cycle. All
experiments using the mice were performed according to
the guidelines for Animal Experimentation, Chiba Cancer
Center, and Chiba University.
2.2. RNA Preparation and RT-PCR Analysis. RNA was
extracted from diﬀerent organs of wild-type and hNEDL1-
Tg mice by using RNeasy Fibrous Tissue Mini Kits (Qiagen,
Valencia, CA, USA) according to the manufacturer’s pro-
tocol; cDNA was generated from 1μg of total RNA using
random primers and SuperScript II reverse transcriptase
(Invitrogen, Carlsbad, CA, USA). PCR was performed
using the cDNA as template with the following primers:
hNEDL1 forward, 5 -TATCAGAAGGTGGTGGCTGGTGT-
GG-3 ,a n dr e v e r s e5  -TATGACTGGGAGTAGTCAGG-
AGAGG-3 ;m o u s eG A P D Hf o r w a r d ,5  -ATCTTCTTGTG-
CAGTGCCAG-3  and reverse 5 -GAGATGATGACCCG-
TTTGGC-3 . PCR products were separated by 2% agarose
gel electrophoresis and visualized by ethidium bromide
staining.Journal of Biomedicine and Biotechnology 3
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Figure 2: Overexpression of hNEDL1 aﬀected the locomotion and rotarod performance. (a) Behavior (locomotion) in the mice was evaluated;
each value (counts per 10min) is the mean ± SEM (n = 11 ∼ 12;
∗P <. 05;
∗∗P <. 01). (b) The rotarod performance of wild-type (white
bar: n = 12) and hNEDL1-Tg mice (black bar: n = 11) from the age of six mounths to ﬁfteen months. Data are mean ± SEM (
∗P <. 05;
∗∗P <. 01).
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Figure 3: Overexpression of hNEDL1 aﬀected the hanging wire and foot print performances. (a) The hanging wire performance of wild-type
(white bar: n = 12) and hNEDL1-Tg mice (black bar: n = 11) from the age of six to ﬁfteen months. Data are mean ± SEM (∗P<. 05;
∗∗P <. 01). (b) The distance between forepaw/hindpaw placements in each stride was recorded and analyzed in the wild type (white bar:
n = 12) and hNEDL1-Tg mice (black bar: n = 11) from the age of six to ﬁfteen months. Data are mean ± SEM (∗P<. 05;
∗∗P <. 01).4 Journal of Biomedicine and Biotechnology
WT hNEDL1-Tg
S
t
r
i
a
t
u
m
H
i
p
p
o
c
a
m
p
u
s
F
r
o
n
t
a
l
c
o
r
t
e
x
L
u
m
b
a
r
s
p
i
n
a
l
c
o
r
d
50μm
20μm
(a)
WT hNEDL1-Tg WT hNEDL1-Tg
Total Degenerated
0
10
20
30
40
50
60
N
u
m
b
e
r
o
f
m
o
t
o
r
n
e
u
r
o
n
∗
(b)
Figure 4: Overexpression of hNEDL1 induced neuron degeneration in lumbar spinal cord and skeletal muscle atrophy. Bodian -stained section
of frontal cortex, hippocampus, striatum (bar = 50μm), and lumbar spinal cord (bar = 20μm). Degenerated motor neurons and decreased
axon are observed in the lumbar spinal cord in the hNEDL1-Tg mouse. The numbers of motor neuron in the total motor neuron and in the
degenerated motor neuron from wild-type mice (white bar: n = 12) and hNEDL1-Tg mice (black bar: n = 11) from the age of six to ﬁfteen
months were shown. Data are mean ± SEM (
∗P <. 05).
2.3. Protein Extraction and Western Blot Analysis. Protein
was extracted from diﬀerent organs of wild-type and
NEDL1-Tg mice, respectively. The extraction was performed
in lysis buﬀer (25mM Tris-HCl, pH 7.5, 137mM NaCl,
2.7mM KCl, 1% Triton X-100, 1mM PMSF, and protease
inhibitor cocktail) (Roche Diagnostics, Mannheim, Ger-
many). Equal amounts of protein were separated in SDS-
polyacrilamide gel and transferred onto PVDF membrane
(MilliporeCorporation,Bedford,MA,USA).Themembrane
was incubated with rabbit polyclonal anti-human-NEDL1
antibodies (raised against C-terminal 17 amino acids of
human NEDL1: SWKPEQLGEGSVPDRPG) (MBL, Japan)
or with rabbit polyclonal anti β-actin antibodies (20−33)
(Sigma, St. Louis, MO, USA), followed by incubation
with the HRP-conjugated secondary antibodies (Jackson
ImmunoResearch Laboratories, West Grove, PA, USA),
respectively. Indicated proteins were visualized by using ECL
system (Amersham Biosciences, Piscataway, NJ, USA).
2.4. Locomotion Test. Locomotor activity was measured
using an animal movement analysis system (SCANET SV-10,
Melquest, Toyama, Japan), as reported previously [13]. The
system consisted of a rectangular enclosure (480−300mm).
The side walls (height: 60mm) of the enclosure were
equipped with 144 pairs of photosensors located at 5mm
intervals at a height of 30mm from the bottom edge. A pair
ofphotosensorswasscannedevery0.1stodetecttheanimal’s
movements.Theintersectionofpairedphotosensors(10mm
apart) in the enclosure was counted as one unit of locomotor
activity. Data collected for 120min were used in this study.
2.5. Rotarod Test. Motor function and skeletal functional
performance were assessed by using rotarod (MK-610A,
Muromachi Kikai, Tokyo, Japan). Eleven male hNEDL1-Tg
and twelve wild-type mice, respectively, were tested during
the age of six to ﬁfteen months old. Each animal was
given 10-minute training before the testing. After getting
acquainted to the apparatus, animals were placed onto the
apparatus at a constant speed of 20r.p.m. (rotating cylinder
was 3.0cm in diameter). The time which an animal could
remain on the rotating rod was recorded in three consecutive
attempts; 300 seconds was chosen as the arbitrary cutoﬀJournal of Biomedicine and Biotechnology 5
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Figure 5: Overexpression of hNEDL1 induced neuron degeneration in lumbar spinal cord and skeletal muscle atrophy. (a) Haematoxylin and
eosin-stained section of skeletal muscle from 6-month-old wild-type and hNEDL1-Tg mice (bar = 100μm). Muscle atrophy is observed
in the hNEDL1-Tg mouse. (b) Immunochemistry study, by using Iba-1 antibody, represented the microglia cells in spinal cord tissue. The
numbers of total microglia cells and the activated microglia cells, which were judged by the morphologic change, were counted.
time. The average time of the three trials was calculated and
analyzed.
2.6. Hanging Wire Test. This task was used as a measure
of muscular strength and motor neuron integrity. Mice
utilized their forelimbs to suspend their body weight on a
wire stretched between two posts 60cm and 20cm above
a foam pillow. The time (in seconds) until the mouse fell
was recorded. A score of zero was assigned if the mouse fell
immediately and 60 seconds was the timeout period. Three
trials were performed for each mouse before the testing day.
2.7. Footprint Test. The limb paws of six-month-old mice
were inked with black (forelimb) and blue ink (hind limb),
and mice were allowed to walk over a white paper strip in a
straight-alley runway (50cm long) to an enclosed goal box.
Tracks were collected, and the fore- and hind limbs stride
length was calculated and analyzed.
2.8. Histological Analysis. Six-month-old wild-type and
hNEDL1-Tg mice were sacriﬁced. The segments of skeletal
muscles were taken from hind legs of both wild-type and
hNEDL1-Tg mice, ﬁxed with 10% formalin, and embedded
in paraﬃn blocks. The 7μm sections were stained for
hematoxylin and eosin. For neuron quantiﬁcation, brain
and spinal cord were isolated from mouse, ﬁxed with 10%
formalin, and embedded in paraﬃn blocks. The paraﬃn
blocks were sliced into 6μm sections, and Bodian staining
was performed. The numbers of motor neuron in the total
motor neuron and in the degenerated motor neuron from
wild-type mice and hNEDL1-Tg mice were measured.
2.9. Immunohistochemsitry. Isolated spinal cord was embed-
ded in Tissue-Tek O.C.T Compound (4583, Sakura Finetek
Japan Co., Ltd., Tokyo, Japan) and frozen in −80 degree.
The frozen spinal cord tissue was sliced into 15μms e c t i o n s ,
and the sections were incubated 1-2h with primary antibody
rabbit anti-Iba-1 (Cat no. 019-19741, Wako Pure Chemical
Industries, Ltd., Osaka, Japan) at room temperature, fol-
lowed by processing the avidin-biotin-peroxidase method
(VectastainEliteABC,VectorLaboratories,Inc.,Burlingame,
CA, USA), as described previously [13, 14].
2.10. Statistical Analysis. Data were expressed as means ±
S.E.M. Statistical analysis was performed using one-way
analysis or two-way analysis of variance (ANOVA). P-values
less than .05 were considered statistically signiﬁcant.
3. Results
3.1. Expression Level of hNEDL1 in Diﬀerent Organic Tissue
in NEDL1-Tg Mouse. To understand the role of NEDL1
involved in pathogenesis of familial ALS, we generated
transgenic mice with the human NEDL1 cDNA driven by
CAG promoter that combines the cytomegalovirus enhancer
and a chicken β-actin promoter and intron (Figure 1(a)).
TheCAGpromoterisaverystrongandubiquitouspromoter,
and allows expressing foreign genes at high levels in vivo
[11]. We obtained four independent hNEDL1-Tg mice lines
and conﬁrmed the hNEDL1 expression in each line (data
not shown), and the hNEDL1-Tg mouse line that showed
the strongest expression level of hNEDL1 was used in
this study. The expression of hNEDL1 in diﬀerent organic
tissue was examined by RT-PCR and Western blotting
analysis. Although the hNEDL1 expression was conﬁrmed
in all tissues, a slightly higher expression of hNEDL1 was
conﬁrmed in brain and skeletal muscle (Figures 1(b) and
1(c)).6 Journal of Biomedicine and Biotechnology
3.2. Expression of hNEDL1 Alters the Functional Performance
of Skeletal Muscle. Since being ﬁve months old, spontaneous
locomotor activity of the hNEDL1-Tg mice was signiﬁcantly
lower than that of wild-type mice (Figure 2(a)). Then, we
assessed the motor neuron function and the performance
of skeletal muscle by rotarod test, hanging wire test, and
foot print test. As shown in the ﬁgures (Figures 2(b) and
3(a)), there are signiﬁcant diﬀerences between hNEDL1-Tg
mice and wild-type mice in the rotarod test (F (1, 21) =
25.392; P<. 001) and hanging wire task (F (1, 21) = 41.173;
P<. 001), during the age from six months to ﬁfteen months.
The footprint test proved an eloquent method of quantifying
themotorfunction;thestridelengthinthehNEDL1-Tgmice
was shortened about 2cm compared with that in the wild-
type mice (Figure 3(b)).
3.3. Motor Neuron Degeneration and Muscular Atrophy
Occurred in the Human NEDL1 Transgenic Mouse. Histo-
logical study showed that there is no degenerated neuron
(Figure 4) nor activated microglia (data not shown) in the
frontal cortex, striatum, and hippocampus of six-month-old
hNEDL1-Tg mice. However, the degenerated motor neurons
and decreased axon were clearly shown in the lumbar
spinal cord, compared to these of the age-matched wild-type
mouse (Figure 4). In addition, signiﬁcant muscle atrophy
was observed in the hNEDL1-Tg mouse (Figure 5(a)).
Immunohistochemsitry study using Iba-1 antibody
showed the detection of microglia in spinal cord. There is
no change of the number of Iba-1 immunoreactive cells
(microglia cells) in both hNEDL1 transgenic mice and wild-
type mice (Figure 5(b)). However, the number of activated
microglia in the hNEDL1 transgenic mice was signiﬁcantly
higher than that of wild-type mice, suggesting that microglia
activation (e.g., inﬂammation) might occur in the lumbar
spinal cord of hNEDL1 transgenic mice (Figure 5(b)).
4. Discussion
In this paper study, we found that the hNEDL1 might
be involved in pathology of ALS-like symptoms, such as
motor neuron degeneration, decreased axon length, and
skeletal muscle atrophy. In the hNEDL1-Tg mice, hNEDL1
is overexpressed ubiquitously in vivo since the promoter
used in this study is the CAG promoter [11]. In fact, the
expression of the hNEDL1 was observed not only in the
central nervous system and muscle but also in the kidney
andliver.Nevertheless,itshouldbenotedthatthephenotype
of the hNEDL1-Tg mice has only been detected in muscular
and nervous system.
There is increasing evidence for the ubiquitin-mediated
proteasome pathway involvement in pathogenesis of neu-
rodegenerative disease, including ALS, Parkinson’s disease,
and Huntington’s disease. These diseases are associated
with degeneration of speciﬁc neuronal populations due to
misfolding or aggregation of certain proteins [12]. These
aggregates are always ubiquitin-positive and insoluble pres-
ence in the Lewy-like inclusion body [15, 16]. Generally, the
inclusion bodies consist of ubiquitinated polypeptides that
fail to be destroyed by the 26S proteasome, and the apparent
stability may be due to decreased levels of 26S proteasomal
activity, which is associated with increasing age [17]o r
mutated SOD1 [18]. Ubiquitin-protein ligases E3 are to
particular importance of the protein quality control system,
since they determine the targeting protein speciﬁcally.
Recently, immunohistochemical analysis revealed that
the NEDL1 and dorﬁn serve as E3 ligases, localized within
the Lewy-like inclusion body in the spinal cord of ALS
patients and mutated SOD1 transgenic mice [9, 10]. They
speciﬁcally interacted with mutated SOD1, but not the wild
type SOD1, and promoted degradation of the mutant SOD1,
protected neuronal cells from the toxicity caused by mutant
SOD1 [9, 10], suggesting the potential role of NEDL1 as
a modiﬁer for familial ALS. Surprisingly, in this study, we
found that overexpression of hNEDL1 in Tg mice caused the
neuron degeneration, neural axon decrease, and microglia
activation in the lumbar spinal cord. Loss of the neuron
and activation of microglia in the central neuron system,
which is a common feature of neurodegenerative disease,
werenotobservedinthebraintissue,butinthespinalcordof
the hNEDL1-Tg mice. Mutant SOD1 physically binds to the
NEDL1 and causes the conformational changes of NEDL1
protein, increasing binding intensity to Dvl 1. That results
in degradation of Dvl 1 and decrease of phosphorylated c-
Jun in the downstream [10]. The abnormality of the NEDL1
E3 ligase activity is responsive for the neuron death in the
spinal cord of the mutant SOD1-Tg mouse, and is also the
considerable reason in the case of hNEDL1-Tg mice. It is
likely that muscular atrophy that occurred in the hNEDL1
transgenic mice may be the consequence of the neuron death
in the spinal cord or the extra NEDL1 expression in the
muscle tissues, like that atrogin-1 (MAFbx), a ubiquitin
ligase is necessary for rapid muscular atrophy [19].
Accumulating evidence suggests that microglial neuro
inﬂammation plays a role in the pathogenesis of ALS [20–
23]. A recent study suggests that the early activity of
microglia is involved in the early phase of motor neuron
degeneration of human mutant SOD1 murine transgenic
model of ALS [23]. In this study, we found that microglial
activation might have occurred in the lumbar spinal cord of
hNEDL1 mice, suggesting that microglial activation may be
involved in the behavioral abnormalities of hNEDL1 mice.
It has been reported that the second-generation antibiotic
drugminocycline,apotentinhibitorofmicroglialactivation,
slows disease progression in a mouse model of ALS [24,
25] and that minocycline attenuates microglial activation
by abused drugs [13, 14]. A number of trophic factors,
antiinﬂammatory agents and inhibitors of oxidative stress
have been reported to prolong survival in mouse models of
ALS and some are now in clinical trials [26, 27]. Therefore,
it may be of interest to examine the eﬀects of minocycline in
the behavioral abnormalities of hNEDL1 transgenic mice.
In conclusion, this study suggests that overexpression of
hNEDL1 might be implicated in the degeneration of motor
neuron in lumbar spinal cord although a further detailed
study underlying the role of the NEDL1 in the pathogenesis
of familial ALS should be necessary. Furthermore, the
elucidation of the mechanisms underlying motor neuronJournal of Biomedicine and Biotechnology 7
pathologyinhNEDL1transgenicmiceshedlightontheearly
pathological events of familial ALS and might then open
avenues for potential therapeutic targets in ALS and other
motor neuron neurodegenerative disorders.
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